Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Major clinical research advances in gynecologic cancer in 2018

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. HPV-prevalence in elderly women in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Nineteen topics were selected as major clinical research advances in gynecologic oncology in 2018. For cervical cancer, the importance of human papillomavirus (HPV) testing alone as primary cervical cancer screening method and negative survival impact of minimally invasive surgery in early-stage cervical cancer were addressed. For ovarian cancer, cost-effectiveness of genetic testing to prevent cancer, use of analgesics and oral pill to reduce cancer risk, efficacy of secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, update in the use of poly (ADP-ribose) polymerase inhibitor, and efficacy of anti-angiogenic targeted treatments, including bevacizumab and tyrosine kinase inhibitors, were reviewed. For corpus cancer, sentinel lymph node mapping technique, adjuvant therapy in high-risk endometrial cancer (PORTEC-3), and targeted therapy in recurrent disease were covered. For the field of radiation oncology, survival outcomes of chemoradiation compared with chemotherapy alone in metastatic cervical cancer and new findings regarding the use of neoadjuvant chemotherapy in locally advanced cervical cancer were introduced. Lastly, for breast cancer, the use of talazoparib in patients with germline BRCA1/2 mutation, ovarian suppression for premenopausal patients, adjuvant chemotherapy guided by 21-gene assay, and combination therapy of atezolizumab and nab-paclitaxel for triple-negative cancer as well as promising overall survival results of palbociclib and fulvestrant in advanced breast cancer were briefly mentioned.

Original languageEnglish
JournalGynecologic Oncology
Volume30
Issue number2
Pages (from-to)e18
ISSN0090-8258
DOIs
Publication statusPublished - Mar 2019

    Research areas

  • Analgesics/administration & dosage, Angiogenesis Inhibitors/therapeutic use, Breast Neoplasms/genetics, Carrier State, Combined Modality Therapy, Contraceptives, Oral, Hormonal/administration & dosage, Cytoreduction Surgical Procedures, Drug Resistance, Neoplasm/genetics, Early Detection of Cancer, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Genetic Testing, Genital Neoplasms, Female/diagnosis, Humans, Hyperthermia, Induced, Hysterectomy/methods, Laparoscopy, Mutation, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use, Sentinel Lymph Node Biopsy

ID: 59074865